CN1296474A - 烷基化用于制备基质金属蛋白酶抑制剂的受阻磺酰胺的方法 - Google Patents

烷基化用于制备基质金属蛋白酶抑制剂的受阻磺酰胺的方法 Download PDF

Info

Publication number
CN1296474A
CN1296474A CN99804961A CN99804961A CN1296474A CN 1296474 A CN1296474 A CN 1296474A CN 99804961 A CN99804961 A CN 99804961A CN 99804961 A CN99804961 A CN 99804961A CN 1296474 A CN1296474 A CN 1296474A
Authority
CN
China
Prior art keywords
aryl
heteroaryl
alkyl
alkoxyl group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99804961A
Other languages
English (en)
Chinese (zh)
Inventor
B·M·安德森
P·D·翰门
J·M·霍金斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1296474A publication Critical patent/CN1296474A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
CN99804961A 1998-04-10 1999-04-09 烷基化用于制备基质金属蛋白酶抑制剂的受阻磺酰胺的方法 Pending CN1296474A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8131098P 1998-04-10 1998-04-10
US60/081,310 1998-04-10

Publications (1)

Publication Number Publication Date
CN1296474A true CN1296474A (zh) 2001-05-23

Family

ID=22163376

Family Applications (3)

Application Number Title Priority Date Filing Date
CN99804961A Pending CN1296474A (zh) 1998-04-10 1999-04-09 烷基化用于制备基质金属蛋白酶抑制剂的受阻磺酰胺的方法
CN99104932A Pending CN1234396A (zh) 1998-04-10 1999-04-09 烷基化受阻磺酰胺的方法
CN00126476A Pending CN1288885A (zh) 1998-04-10 2000-08-25 受阻磺酰胺的烷基化方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN99104932A Pending CN1234396A (zh) 1998-04-10 1999-04-09 烷基化受阻磺酰胺的方法
CN00126476A Pending CN1288885A (zh) 1998-04-10 2000-08-25 受阻磺酰胺的烷基化方法

Country Status (47)

Country Link
US (2) US6114568A (enExample)
EP (2) EP0949245B1 (enExample)
JP (2) JP3479511B2 (enExample)
KR (2) KR100357660B1 (enExample)
CN (3) CN1296474A (enExample)
AP (1) AP1095A (enExample)
AR (1) AR017731A1 (enExample)
AT (2) ATE206392T1 (enExample)
AU (2) AU760213B2 (enExample)
BG (1) BG63665B1 (enExample)
BR (2) BR9910110A (enExample)
CA (2) CA2268684C (enExample)
CO (1) CO4810299A1 (enExample)
DE (2) DE69900321T2 (enExample)
DK (1) DK0949245T3 (enExample)
DZ (1) DZ2754A1 (enExample)
EA (1) EA002277B1 (enExample)
EG (1) EG21985A (enExample)
ES (2) ES2163316T3 (enExample)
GT (1) GT199900047A (enExample)
HN (1) HN1999000043A (enExample)
HR (1) HRP990106B1 (enExample)
HU (2) HUP9901043A1 (enExample)
ID (2) ID23244A (enExample)
IL (2) IL129168A (enExample)
IN (1) IN192485B (enExample)
IS (1) IS5018A (enExample)
MA (1) MA24833A1 (enExample)
NO (1) NO991675L (enExample)
NZ (1) NZ335105A (enExample)
OA (1) OA11030A (enExample)
PA (1) PA8469601A1 (enExample)
PE (1) PE20000417A1 (enExample)
PL (2) PL332451A1 (enExample)
PT (1) PT949245E (enExample)
RU (1) RU2197479C2 (enExample)
SA (1) SA99200089A (enExample)
SG (1) SG75167A1 (enExample)
SK (1) SK45399A3 (enExample)
TN (1) TNSN99054A1 (enExample)
TR (2) TR199900756A2 (enExample)
TW (1) TW520354B (enExample)
UA (1) UA57039C2 (enExample)
UY (1) UY25469A1 (enExample)
WO (1) WO1999052862A1 (enExample)
YU (1) YU18399A (enExample)
ZA (2) ZA992627B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
EP1134207A1 (en) * 2000-03-15 2001-09-19 Pfizer Products Inc. Process for preparing resorcinol derivatives
US6548667B2 (en) 2000-04-07 2003-04-15 Samsung Electronics Co. Ltd. Sulfonamide derivative as a matrix metalloproteinase inhibitor
US20020073441A1 (en) 2000-12-13 2002-06-13 Ross Brian D. Compositions and methods for detecting proteolytic activity
US6844373B2 (en) * 2002-05-28 2005-01-18 Alcatel Composition comprising fluorinated, radiation-curable dyes for surface energy control
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
ITBO20050005U1 (it) * 2005-01-31 2006-08-01 Ali Spa Distributore di bevande ghiacciate e simili

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU523636A3 (ru) * 1973-06-18 1976-07-30 Стауффер Кемикал Компани (Фирма) Способ получени сульфоксидных или сульфоновых производных тиокарбаматов
ZA794723B (en) 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
GB9000725D0 (en) 1990-01-12 1990-03-14 Pfizer Ltd Therapeutic agents
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0922030A1 (en) * 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
HUP0000852A2 (hu) 1997-02-03 2001-05-28 Pfizer Products Inc. Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
TR200000368T2 (tr) 1997-08-08 2000-07-21 Pfizer Products Inc. Ariloksiariarilsülfonilamino hidroksamik asit türevleri.
DE69805473T2 (de) 1997-08-08 2003-01-16 Pfizer Products Inc., Groton Arylsulfonylaminohydroxamsäurederivate
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico

Also Published As

Publication number Publication date
JP2000026400A (ja) 2000-01-25
BG63665B1 (bg) 2002-08-30
AU760213B2 (en) 2003-05-08
DE69922638D1 (de) 2005-01-20
TR200002950T2 (tr) 2000-12-21
SK45399A3 (en) 2000-08-14
HN1999000043A (es) 1999-11-03
UY25469A1 (es) 1999-11-17
ATE206392T1 (de) 2001-10-15
HUP0101465A3 (en) 2002-11-28
AU2369199A (en) 1999-10-21
KR100357660B1 (ko) 2002-10-25
TR199900756A2 (xx) 1999-11-22
AU3552799A (en) 1999-11-01
JP3540959B2 (ja) 2004-07-07
HUP0101465A2 (hu) 2002-03-28
UA57039C2 (uk) 2003-06-16
IL138778A0 (en) 2001-10-31
PT949245E (pt) 2002-02-28
EA002277B1 (ru) 2002-02-28
NO991675L (no) 1999-10-11
EG21985A (en) 2002-05-31
NO991675D0 (no) 1999-04-09
KR19990082986A (ko) 1999-11-25
ATE284864T1 (de) 2005-01-15
EP0949245B1 (en) 2001-10-04
NZ335105A (en) 2000-03-27
YU18399A (sh) 2002-11-15
AR017731A1 (es) 2001-09-12
CA2268684C (en) 2004-07-13
US6114568A (en) 2000-09-05
DZ2754A1 (fr) 2003-09-15
DK0949245T3 (da) 2002-01-28
MA24833A1 (fr) 1999-12-31
EA199900277A3 (ru) 2000-04-24
EP1068180B1 (en) 2004-12-15
AP1095A (en) 2002-08-26
BG103320A (en) 2001-08-31
BR9902219A (pt) 2000-04-11
CA2327498C (en) 2006-01-31
IL129168A0 (en) 2000-02-17
DE69922638T2 (de) 2005-05-19
ID27208A (id) 2001-03-08
GT199900047A (es) 2000-09-15
EA199900277A2 (ru) 1999-10-28
DE69900321T2 (de) 2002-07-11
CN1288885A (zh) 2001-03-28
IN192485B (enExample) 2004-04-24
HRP990106B1 (en) 2003-08-31
JP2002511447A (ja) 2002-04-16
BR9910110A (pt) 2001-10-09
PE20000417A1 (es) 2000-05-24
PA8469601A1 (es) 2000-09-29
TNSN99054A1 (fr) 2005-11-10
SA99200089A (ar) 2005-12-03
PL332451A1 (en) 1999-10-11
AP9901506A0 (en) 1999-06-30
KR100377718B1 (ko) 2003-03-26
RU2197479C2 (ru) 2003-01-27
CA2327498A1 (en) 1999-10-21
CA2268684A1 (en) 1999-10-10
ZA200005370B (en) 2002-01-03
CO4810299A1 (es) 1999-06-30
SG75167A1 (en) 2000-09-19
HUP9901043A1 (hu) 2000-08-28
EP1068180A1 (en) 2001-01-17
CN1234396A (zh) 1999-11-10
ID23244A (id) 2000-03-30
EP0949245A1 (en) 1999-10-13
DE69900321D1 (de) 2001-11-08
IS5018A (is) 1999-10-11
PL343530A1 (en) 2001-08-27
OA11030A (en) 2002-02-07
US6229025B1 (en) 2001-05-08
JP3479511B2 (ja) 2003-12-15
KR20010042567A (ko) 2001-05-25
IL129168A (en) 2003-07-06
AU755004B2 (en) 2002-11-28
ES2163316T3 (es) 2002-01-16
HRP990106A2 (en) 1999-12-31
WO1999052862A1 (en) 1999-10-21
TW520354B (en) 2003-02-11
ES2234253T3 (es) 2005-06-16
HU9901043D0 (en) 1999-06-28
ZA992627B (en) 2000-10-09

Similar Documents

Publication Publication Date Title
CN1222518C (zh) 锌荧光探针
CN1296481A (zh) (4－芳基磺酰氨基)－四氢吡喃－4－羧酸羟基酰胺
CN1756734A (zh) 谷氨酸衍生物和焦谷氨酸衍生物的制造方法和新型的制造用中间体
CN1234679C (zh) 3,3－二芳基丙基胺衍生物的简化合成法
CN1148382A (zh) 用于光学拆分外消旋α-[4-(1，1-二甲基乙基)苯基]-4-(羟基二苯基甲基)-1-哌啶丁醇和其衍生化合物的方法和非对映体盐
CN1229347C (zh) 制备哌啶衍生物非索非那定的方法
CN1164577C (zh) 2-氨基-4-(4-氟苯基)-6-烷基嘧啶-5-羧酸酯的制备方法
CN1377337A (zh) 苯乙酸衍生物的制备方法
CN1184109A (zh) 对映体纯环烷醇吲哚羧酸和氮杂吲哚羧酸和嘧啶并[1,2－a]－吲哚羧酸及其活性衍生物的制备方法
CN1349501A (zh) 三环氨基衍生物的新的制备方法
CN1086809A (zh) 5-氧代-二苯并[a，d]环庚-1，4-二烯
CN1305989A (zh) 新型苯磺酰胺化合物、其制备方法和含有其的药物组合物
CN1958593A (zh) 一种用于合成瑞舒伐他汀钙的中间体的制备方法
CN1247581C (zh) 卡巴培南类抗菌剂的制造方法
CN1315319A (zh) 乙磺酰哌啶衍生物的制备方法
CN1264792C (zh) 一种制备α’氯代酮类的方法
CN1234396A (zh) 烷基化受阻磺酰胺的方法
HK1036270A (en) Process for alkylating hindered sulfonamides useful in the production of matrix metal-loproteinase inhibitors
CN1360574A (zh) 制备三环氨基醇衍生物的方法
CN1103761C (zh) 制备1－取代－乙内酰脲的方法
CN1028023C (zh) 戊二酸衍生物的制备
CN1160350C (zh) 制备手性内酯的方法
CN1578760A (zh) (2－硝基苯)乙腈衍生物的制造方法及其合成中间体
CN1671704A (zh) 制备吲哚－2,3－二酮－3－肟衍生物的对映异构体的方法
CN1735588A (zh) 由d－和l－天冬氨酸合成(r)和(s)－氨基肉碱及其衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1036270

Country of ref document: HK